In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin

Zeruesenay Desta, Nadia Soukhova, David A. Flockhart

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pimozide is often coprescribed with serotonin reuptake inhibitor (SSRI) antidepressants to treat depression in patients with Tourette's syndrome. In human liver microsomes (HLMs), the inhibition of the primary route of pimozide metabolism, N-dealkylation to 1,3-dihydro-l-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI), by four SSRIs (fluoxetine, sertraline, paroxetine, and fluvoxamine) and azithromycin was tested. Inhibition constants (Ki values) were estimated from Dixon plots (three HLMs for each inhibitor) using the appropriate enzyme inhibition model by nonlinear regression. At 10 μM paroxetine, sertraline, fluoxetine, or fluvoxamine, the formation of DHPBI from pimozide (10 μM) in HLMs was inhibited by an average (three HLMs) of 7%, 7.7%, 8%, and 16%, respectively, whereas this inhibition did not exceed 55% at the maximum concentrations (100 μM) of the SSRIs tested. Azithromycin had negligible effect on pimozide (10 μM) N-dealkylation (19% at 100 μM azithromycin). These inhibition data were compared with ketoconazole, which was included as a positive control of CYP3A inhibition. At 0.1 μM and 0.5 μM ketoconazole, the formation of DHPBI from 10 μM pimozide was inhibited by 32% and 62%, respectively. The Ki values (± SD) of ketoconazole, sertraline, fluvoxamine, azithromycin, fluoxetine, and paroxetine were 0.07 μM, 89 ± 44 μM, 89 ± 24 μM, 103 ± 52 μM, 117 ± 27 μM, and 129 ± 33 μM, respectively. These values are least 100-fold higher than the expected plasma concentrations after the usual daily doses of the SSRIs and azithromycin, suggesting that coadministration of SSRIs and azithromycin are unlikely to markedly diminish the elimination of pimozide in patients. However, in vivo predictions from in vitro data are not always perfect. In vivo, the SSRIs or azithromycin may concentrate in the liver relative to plasma. In addition, the possibility that these drugs could alter pimozide disposition through effects on transport proteins or via promoter repression cannot be ruled out.

Original languageEnglish
Pages (from-to)162-168
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume22
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Dealkylation
Pimozide
Azithromycin
Serotonin Uptake Inhibitors
Liver Microsomes
Fluvoxamine
Sertraline
Paroxetine
Ketoconazole
Fluoxetine
Cytochrome P-450 CYP3A
Tourette Syndrome
In Vitro Techniques
Inhibition (Psychology)
Antidepressive Agents
Carrier Proteins
Depression
Liver
Enzymes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. / Desta, Zeruesenay; Soukhova, Nadia; Flockhart, David A.

In: Journal of Clinical Psychopharmacology, Vol. 22, No. 2, 2002, p. 162-168.

Research output: Contribution to journalArticle

@article{45843d6fc9ea467e83246113f55372f4,
title = "In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin",
abstract = "Pimozide is often coprescribed with serotonin reuptake inhibitor (SSRI) antidepressants to treat depression in patients with Tourette's syndrome. In human liver microsomes (HLMs), the inhibition of the primary route of pimozide metabolism, N-dealkylation to 1,3-dihydro-l-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI), by four SSRIs (fluoxetine, sertraline, paroxetine, and fluvoxamine) and azithromycin was tested. Inhibition constants (Ki values) were estimated from Dixon plots (three HLMs for each inhibitor) using the appropriate enzyme inhibition model by nonlinear regression. At 10 μM paroxetine, sertraline, fluoxetine, or fluvoxamine, the formation of DHPBI from pimozide (10 μM) in HLMs was inhibited by an average (three HLMs) of 7{\%}, 7.7{\%}, 8{\%}, and 16{\%}, respectively, whereas this inhibition did not exceed 55{\%} at the maximum concentrations (100 μM) of the SSRIs tested. Azithromycin had negligible effect on pimozide (10 μM) N-dealkylation (19{\%} at 100 μM azithromycin). These inhibition data were compared with ketoconazole, which was included as a positive control of CYP3A inhibition. At 0.1 μM and 0.5 μM ketoconazole, the formation of DHPBI from 10 μM pimozide was inhibited by 32{\%} and 62{\%}, respectively. The Ki values (± SD) of ketoconazole, sertraline, fluvoxamine, azithromycin, fluoxetine, and paroxetine were 0.07 μM, 89 ± 44 μM, 89 ± 24 μM, 103 ± 52 μM, 117 ± 27 μM, and 129 ± 33 μM, respectively. These values are least 100-fold higher than the expected plasma concentrations after the usual daily doses of the SSRIs and azithromycin, suggesting that coadministration of SSRIs and azithromycin are unlikely to markedly diminish the elimination of pimozide in patients. However, in vivo predictions from in vitro data are not always perfect. In vivo, the SSRIs or azithromycin may concentrate in the liver relative to plasma. In addition, the possibility that these drugs could alter pimozide disposition through effects on transport proteins or via promoter repression cannot be ruled out.",
author = "Zeruesenay Desta and Nadia Soukhova and Flockhart, {David A.}",
year = "2002",
doi = "10.1097/00004714-200204000-00009",
language = "English",
volume = "22",
pages = "162--168",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin

AU - Desta, Zeruesenay

AU - Soukhova, Nadia

AU - Flockhart, David A.

PY - 2002

Y1 - 2002

N2 - Pimozide is often coprescribed with serotonin reuptake inhibitor (SSRI) antidepressants to treat depression in patients with Tourette's syndrome. In human liver microsomes (HLMs), the inhibition of the primary route of pimozide metabolism, N-dealkylation to 1,3-dihydro-l-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI), by four SSRIs (fluoxetine, sertraline, paroxetine, and fluvoxamine) and azithromycin was tested. Inhibition constants (Ki values) were estimated from Dixon plots (three HLMs for each inhibitor) using the appropriate enzyme inhibition model by nonlinear regression. At 10 μM paroxetine, sertraline, fluoxetine, or fluvoxamine, the formation of DHPBI from pimozide (10 μM) in HLMs was inhibited by an average (three HLMs) of 7%, 7.7%, 8%, and 16%, respectively, whereas this inhibition did not exceed 55% at the maximum concentrations (100 μM) of the SSRIs tested. Azithromycin had negligible effect on pimozide (10 μM) N-dealkylation (19% at 100 μM azithromycin). These inhibition data were compared with ketoconazole, which was included as a positive control of CYP3A inhibition. At 0.1 μM and 0.5 μM ketoconazole, the formation of DHPBI from 10 μM pimozide was inhibited by 32% and 62%, respectively. The Ki values (± SD) of ketoconazole, sertraline, fluvoxamine, azithromycin, fluoxetine, and paroxetine were 0.07 μM, 89 ± 44 μM, 89 ± 24 μM, 103 ± 52 μM, 117 ± 27 μM, and 129 ± 33 μM, respectively. These values are least 100-fold higher than the expected plasma concentrations after the usual daily doses of the SSRIs and azithromycin, suggesting that coadministration of SSRIs and azithromycin are unlikely to markedly diminish the elimination of pimozide in patients. However, in vivo predictions from in vitro data are not always perfect. In vivo, the SSRIs or azithromycin may concentrate in the liver relative to plasma. In addition, the possibility that these drugs could alter pimozide disposition through effects on transport proteins or via promoter repression cannot be ruled out.

AB - Pimozide is often coprescribed with serotonin reuptake inhibitor (SSRI) antidepressants to treat depression in patients with Tourette's syndrome. In human liver microsomes (HLMs), the inhibition of the primary route of pimozide metabolism, N-dealkylation to 1,3-dihydro-l-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI), by four SSRIs (fluoxetine, sertraline, paroxetine, and fluvoxamine) and azithromycin was tested. Inhibition constants (Ki values) were estimated from Dixon plots (three HLMs for each inhibitor) using the appropriate enzyme inhibition model by nonlinear regression. At 10 μM paroxetine, sertraline, fluoxetine, or fluvoxamine, the formation of DHPBI from pimozide (10 μM) in HLMs was inhibited by an average (three HLMs) of 7%, 7.7%, 8%, and 16%, respectively, whereas this inhibition did not exceed 55% at the maximum concentrations (100 μM) of the SSRIs tested. Azithromycin had negligible effect on pimozide (10 μM) N-dealkylation (19% at 100 μM azithromycin). These inhibition data were compared with ketoconazole, which was included as a positive control of CYP3A inhibition. At 0.1 μM and 0.5 μM ketoconazole, the formation of DHPBI from 10 μM pimozide was inhibited by 32% and 62%, respectively. The Ki values (± SD) of ketoconazole, sertraline, fluvoxamine, azithromycin, fluoxetine, and paroxetine were 0.07 μM, 89 ± 44 μM, 89 ± 24 μM, 103 ± 52 μM, 117 ± 27 μM, and 129 ± 33 μM, respectively. These values are least 100-fold higher than the expected plasma concentrations after the usual daily doses of the SSRIs and azithromycin, suggesting that coadministration of SSRIs and azithromycin are unlikely to markedly diminish the elimination of pimozide in patients. However, in vivo predictions from in vitro data are not always perfect. In vivo, the SSRIs or azithromycin may concentrate in the liver relative to plasma. In addition, the possibility that these drugs could alter pimozide disposition through effects on transport proteins or via promoter repression cannot be ruled out.

UR - http://www.scopus.com/inward/record.url?scp=0036216315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036216315&partnerID=8YFLogxK

U2 - 10.1097/00004714-200204000-00009

DO - 10.1097/00004714-200204000-00009

M3 - Article

VL - 22

SP - 162

EP - 168

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -